Abstract
Lividomycin (LVM) is a new aminoglycoside antibiotic produced in Japan.The laboratory and clinical studies have been carried out on this drug, and the following results were obtained.The antibacterial activity of LVM against Pseudomonas aeruginosa to be four times or more as great as that of kanamycin (KM).The resistant strains of which exceeded 100 mcg/ml were not found and 68% of tested strains showed MIC of 25 mcg/ml. Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Citrobacter and Enterobacter cloaca seem to have a certain degree of cross-resistance to KM and LVM, but KM is two to four times more effective than LVM antibacterial activities against these organisms.
